Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 5.71% | -46.05% | -95.01% | ||
| Total Receivables | 145.45% | 228.57% | 10.00% | ||
| Inventory | -- | -- | -- | ||
| Prepaid Expenses | 0.00% | -95.76% | 0.00% | ||
| Finance Division Loans and Leases Current | -- | -- | -- | ||
| Total Finance Division Other Current Assets | -- | -- | -- | ||
| Other Current Assets | 1.52% | 1,814.29% | 1,785.71% | ||
| Total Current Assets | 4.48% | -4.74% | -57.10% | ||
|
|
|||||
| Total Current Assets | 4.48% | -4.74% | -57.10% | ||
| Net Property, Plant & Equipment | -50.00% | -93.33% | -98.81% | ||
| Long-term Investments | -- | -- | -- | ||
| Goodwill | -- | -- | -- | ||
| Total Other Intangibles | -- | -- | -- | ||
| Finance Div Loans & Leases LT | -- | -- | -- | ||
| Total Finance Div Other LT Assets | -- | -- | -- | ||
| Total Other Assets | -- | -- | -- | ||
| Total Assets | 4.31% | -6.73% | -61.42% | ||
|
|
|||||
| Total Accounts Payable | 36.12% | 68.52% | 78.14% | ||
| Total Accrued Expenses | 3.70% | -- | -88.61% | ||
| Short-term Debt | 338.13% | -- | -- | ||
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | ||
| Finance Division Debt Current | -- | -- | -- | ||
| Total Finance Division Other Current Liabilities | -- | -- | -- | ||
| Total Other Current Liabilities | -- | -- | -- | ||
| Total Current Liabilities | 95.50% | 169.16% | 80.35% | ||
|
|
|||||
| Total Current Liabilities | 95.50% | 169.16% | 80.35% | ||
| Long-Term Debt | -- | -- | -- | ||
| Short-term Debt | 338.13% | -- | -- | ||
| Capital Leases | -- | -- | -- | ||
| Finance Division Debt Non Current | -- | -- | -- | ||
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | ||
| Total Other Liabilities | -- | -- | -- | ||
| Total Liabilities | 95.50% | 169.16% | 80.35% | ||
|
|
|||||
| Common Stock & APIC | 0.14% | 0.41% | 1.48% | ||
| Retained Earnings | -2.16% | -4.41% | -4.44% | ||
| Treasury Stock & Other | 18.76% | -- | -- | ||
| Total Common Equity | -113.52% | -231.02% | -558.30% | ||
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | ||
| Preferred Stock Non Redeemable | -- | -- | -- | ||
| Preferred Stock Convertible | -- | -- | -- | ||
| Preferred Stock, Others | -- | -- | -- | ||
| Total Preferred Equity | -- | -- | -- | ||
|
|
|||||
| Total Common Equity | -113.52% | -231.02% | -558.30% | ||
| Total Preferred Equity | -- | -- | -- | ||
| Total Minority Interest | -- | -- | -- | ||
| Total Equity | -113.52% | -231.02% | -558.30% | ||
|
|
|||||